284462-56-2

Basic information

• Product Name: 3-(4-AMINOPHENOXY)-N-METHYLBENZAMIDE
• Synonyms: 3-(4-AMINOPHENOXY)-N-METHYLBENZAMIDE
• CAS NO: 284462-56-2
• Molecular Formula: C₁₄H₁₄N₂O₂
• Molecular Weight: 242.27
• Mol File: 284462-56-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-AMINOPHENOXY)-N-METHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-AMINOPHENOXY)-N-METHYLBENZAMIDE(284462-56-2)
• EPA Substance Registry System: 3-(4-AMINOPHENOXY)-N-METHYLBENZAMIDE(284462-56-2)

Safety Data

• Hazardous Substances Data: 284462-56-2(Hazardous Substances Data)

Usage

General Description

The chemical 3-(4-aminophenoxy)-N-methylbenzamide, also known as aminophenoxybenzamidemethyl, is a compound with the molecular formula C14H14N2O2. It is an organic compound that consists of a benzamide group substituted with an aminophenoxy and a methyl group. This chemical has potential applications in the field of pharmaceuticals because of its structural properties, particularly in drug development. However, its specific uses and properties have not been widely documented, and further research may be needed to fully understand its potential applications.

Upstream product

• 71708-64-0 N-methyl-3-(4-nitrophenoxy)benzamide 
• 350-46-9 4-Fluoronitrobenzene 
• 7781-98-8 ethyl-3-hydroxybenzoate 
• 284462-54-0 4-(1-oxoisoindolin-5-yloxy)aniline 
• 3535-88-4 5-tert-butyl-2-methoxyaniline 

Downstream Products

• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 75919-92-5 1-(4-(4-nitrophenoxy)phenyl)ethanone 

Relevant articles and documents

Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors

Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fita€ protocol to improve the homology models of 5-HT2A receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT2A models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, Ki = 1959, 56, and 417 nM against 5-HT 2A, 5-HT2B, and 5-HT2C, respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-targeta€ 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.